Our Take
A hospital chain with solid EBITDA margins (20.9% in FY2026) is returning to public markets after shelving an IPO attempt in 2024—the timing suggests debt refinancing and expansion capital, not distress.
Why it matters
This is the second IPO attempt by a specialty hospital operator in India's tertiary care sector. For investors tracking healthcare infrastructure and bed capacity plays, the filing reveals which operators have achieved scale and profitability to justify public ownership.
Do this week
Healthcare investors: review the DRHP when published on Sebi's site to confirm debt-to-EBITDA ratios and margin sustainability across the eight existing hospitals before the Ludhiana and Gurugram expansions begin.
Paras Healthcare revives IPO after two years on hold
Paras Healthcare Ltd, operating 2,211 beds across eight hospitals in Haryana, Bihar, Uttar Pradesh, Rajasthan, Jharkhand, and Jammu & Kashmir, filed preliminary papers with Sebi on Thursday for an IPO of up to Rs 1,800 crore. The issue comprises Rs 500 crore in fresh equity and Rs 1,300 crore in secondary shares sold by promoter Dharminder Kumar Nagar and other existing investors (per the DRHP filing).
The company intends to use fresh issue proceeds for debt repayment at its holding company and subsidiary PMHPL, with remaining capital allocated to general corporate purposes. In fiscal 2026, Paras Healthcare reported consolidated revenue of Rs 1,605.95 crore and EBITDA of Rs 335.58 crore (per company filing).
This is the company's second approach to public markets. It filed IPO papers with Sebi in 2024, received regulatory approval, and then withdrew the application. JM Financial, BofA Securities India, and Nuvama Wealth Management are appointed as book-running lead managers. Listing is proposed on BSE and NSE.
Planned capacity growth
Paras Healthcare plans to add a 300-bed facility in Gurugram by fiscal 2027 and a 500-bed facility in Ludhiana by fiscal 2028. These additions would increase total capacity to 3,011 beds by March 31, 2028, a 36% expansion from current levels (per company disclosure).
Debt refinancing and execution risk are the real tests
The IPO structure—70% secondary, 28% primary capital—signals that existing investors are partially cashing out and that debt reduction is urgent. An EBITDA margin of 20.9% (per FY2026 results) is healthy for specialty hospitals, but leverage metrics will determine whether this is a disciplined capital raise or a rescue.
The expansion timeline is ambitious. Adding 800 beds across two large geographies in two years requires operational execution, regulatory approvals, and staffing ramp-up. Hospital IPOs in India have historically faced post-listing margin compression if bed utilization or average revenue per bed decline during expansion phases. The company has not published utilization rates or capacity metrics for the existing eight hospitals, so investors lack a baseline to assess execution risk.
The withdrawal of the 2024 IPO application is also noteworthy. Market conditions, debt refinancing windows, or internal triggers could have driven the delay. The relaunch suggests either improved conditions or pressing capital needs.
What to scrutinize in the prospectus
Once the full prospectus is published, audit three metrics: current bed occupancy rates and average revenue per bed across the eight hospitals; debt-to-EBITDA ratio and any debt covenants tied to the fresh capital raise; and capex requirements and timelines for the two expansion projects. Paras Healthcare's specialty care positioning (tertiary and quaternary services) differentiates it from multi-specialty chains, but cost control during expansion is the key to post-IPO performance.